Nava-Gómez J, Ortega-Barnet KY, Jiménez-Báez MV

Language: Spanish
References: 17
Page: 123-128
PDF size: 424.49 Kb.

ABSTRACT

Eradication of Helicobacter pylori infection has been variably associated with a platelet response in patients with immune thrombocytopenic purpura. Several theories have been proposed to explain facthe platelet response to anti-Helicobacter pylori therapy, including molecular mimicry, platelet aggregation and the induction of a Th1 phenotype that favors the onset and/or persistence of immune thrombocytopenic purpura. There are many studies from different countries about the prevalence and effectiveness of the platelet response when the eradication of H. pylori was complete. At some countries, like Japan, Italy and Colombia, there has been good responses. This could be because of a positive specific strain of H. pylori, it could also be because of the patients’ age and their immune system. In conclusion, due to the low costs of the methods of H. pylori detection and treatment, its diagnosis in patients with immune thrombocytopenic purpura should be routinely.

REFERENCES

1. Neunert C, Lim W, Crowther M, Cohen A, et al. The American Society of Hematology 2011 evidence-based practice guideline for autoimmune thrombocytopenia. Blood 2011;117:4190-4207.Consultado el 12 abril de 2016. Disponible en: http://www.bloodjournal.org/content/ 117/16/4190

2. Graham DY, Sung JJ. Helicobacter pylori. En: Feldman M, Friedman LS, Brandt LJ, directores. Selisenger y Fordtran. Enfermedades digestivas y hepáticas: fisiopatología, diagnóstico y tratamiento. 8ª ed. Madrid: Elsevier 2008;1049- 1062.

3. Hwang JJ, Lee DH, Yoon H, Shin CM, et al. The effects of Helicobacter pylori eradication therapy for chronic idiopathic thrombocytopenic purpura. Gut Liver 2015:1-6. Consultado el 12 abril de 2016. Disponible en: http://www.gutnliver. org/journal/view.html?doi=10.5009/gnl14483

4. Takashani, et al. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura. Br J Haematol 2004;124:91-96. Consultado el 12 de abril de 2016. Disponible en<. http://www.ncbi.nlm. nih.gov/pubmed/14675413

5. Abdollahi A, Shoar S, Ghasemi S, Zohreh OY. Is Helicobacter pylori infection a risk factor for idiopathic thrombocytopenic purpura in children? Ann Afr Med 2015;14:177-181. Consultado el 12 de abril de 2016. Disponible en: http:// www.annalsafrmed.org/article.asp?issn=1596-3519;yea r=2015;volume=14;issue=4;spage=177;epage=181;aula st=Abdollahi

6. Brito HS, Braga JA, Loggetto SR, Machado RS, et al. Helicobacter pylori infection and immune thrombocytopenic purpura in children and adolescents: a randomized controlled trial. Platelets 2015;26:336-341. Consultado el 12 de abril de 2016. Disponible en http://www.ncbi.nlm.nih. gov/pubmed/24832381

7. Estrada-Gómez RA, Parra-Ortega I, Martínez-Barreda C, Ruiz-Argüelles GJ. Helicobacter pylori infection and thrombocytopenia: a single-institution experience in México. Rev Invest Clín 2007;59:112-115.

8. Emilia G, et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007;110:3833-3841. Consultado el 12 de abril de 2016. Disponible en http://www. bloodjournal.org/content/bloodjournal/110/12/3833.full. pdf?sso-checked=true

9. Cheng YS, Kuang LP, Zhuang CL, Jiang JD, Shi M. Effects of cytotoxin-associated gene A (CagA) positive Helicobacter pylori infection on anti-platelet glycoprotein antibody producing B cells in patients with primary idiopathic thrombocytopenic purpura (ITP). Pak J Med Sci 2015;31:121-126. Consultado 12 abril del 2016. Disponible en http://www. ncbi.nlm.nih.gov/pmc/articles/PMC4386170/

10. Pérez-Pérez GI, et al. Country-specific constancy by age in cagA+ proportion of Helicobacter pylori infections. Int J Cancer 1997;72:453-456. Consultado el 12 abril de 2016. Disponible en http://www.ncbi.nlm.nih.gov/pubmed/ 9247289

11. Berchtold P, Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993;81:1246-1250. Consultado el 12 de abril de 2016. Disponible en http://www.bloodjournal.org/content/ bloodjournal/81/5/1246.full.pdf?sso-checked=true

12. Kim, et al. Efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenia patients with moderate thrombocytopenia. Ann Hematol 2014;94:739-746. Consultado el 12 de abril de 2016. Disponible en http://www.ncbi.nlm.nih.gov/ pubmed/25501820

13. Chambers HE. Inhibidores de la síntesis de proteína y otros antibacterianos. En: Brunton LL, Lazo JS, Parker KL, editores. Goodman y Gillman. Las bases farmacológicas de la terapéutica. 11a ed. México: McGraw Hill 2006;1182-1188.

14. Michel M, Cooper N, Jean C, Frissora C, Bussel J. Does Helicobacter pylori initiate or perpetuate immune thombocytopenic purpura? Blood 2004;103:890-896. Consultado el 12 de abril de 2016. Disponible en: http://www.bloodjournal. org/content/103/3/890

15. Stasi R, Provan D. Helicobacter pylori and chronic ITP. Hematology Am Soc Hematol Educ Program 2008;206- 212. Consultado 12 abril del 2016. Disponible en: http://asheducationbook.hematologylibrary.org/content/ 2008/1/206.long

16. Stasi R, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009;113:1231-1240. Consultado el 12 de abril de 2016. Disponible en: http:// www.bloodjournal.org/content/bloodjournal/113/6/1231. full.pdf?sso-checked=true

17. Ianaro A, et al. Anti-inflammatori activity of macrolide antibiotics. J Pharmacol Exp Ther 2000;292:156-163. Consultado el 12 de abril de 2016. Disponible en http:// www.ncbi.nlm.nih.gov/pubmed/10604943